{"id":"https://openalex.org/W2007231806","doi":"https://doi.org/10.1016/j.nmd.2007.06.086","title":"G.P.3.11 Novel myostatin inhibitors increase muscle mass in wild-type and mdx mice","display_name":"G.P.3.11 Novel myostatin inhibitors increase muscle mass in wild-type and mdx mice","publication_year":2007,"publication_date":"2007-09-08","ids":{"openalex":"https://openalex.org/W2007231806","doi":"https://doi.org/10.1016/j.nmd.2007.06.086","mag":"2007231806"},"language":"en","primary_location":{"id":"doi:10.1016/j.nmd.2007.06.086","doi":"https://doi.org/10.1016/j.nmd.2007.06.086","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.nmd.2007.06.086","pdf_url":null,"source":{"id":"https://openalex.org/S50004817","display_name":"Neuromuscular Disorders","issn_l":"0960-8966","issn":["0960-8966","1873-2364"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuromuscular Disorders","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041514565","display_name":"Jennifer L. Lachey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112018","display_name":"Acceleron Pharma (United States)","ror":"https://ror.org/023annq56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112018"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"J. Lachey","raw_affiliation_strings":["Acceleron Pharma, Cambridge, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acceleron Pharma, Cambridge, United States","institution_ids":["https://openalex.org/I4210112018"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083364536","display_name":"Abigail E. Pullen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112018","display_name":"Acceleron Pharma (United States)","ror":"https://ror.org/023annq56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112018"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Pullen","raw_affiliation_strings":["Acceleron Pharma, Cambridge, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acceleron Pharma, Cambridge, United States","institution_ids":["https://openalex.org/I4210112018"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102716588","display_name":"Robert Scott Pearsall","orcid":"https://orcid.org/0000-0002-7095-5246","observed_orcids":["https://orcid.org/0000-0002-7095-5246"]},"institutions":[{"id":"https://openalex.org/I4210112018","display_name":"Acceleron Pharma (United States)","ror":"https://ror.org/023annq56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112018"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Pearsall","raw_affiliation_strings":["Acceleron Pharma, Cambridge, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acceleron Pharma, Cambridge, United States","institution_ids":["https://openalex.org/I4210112018"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052288239","display_name":"Jasbir S. Seehra","orcid":"https://orcid.org/0009-0002-0843-8974","observed_orcids":["https://orcid.org/0009-0002-0843-8974"]},"institutions":[{"id":"https://openalex.org/I4210112018","display_name":"Acceleron Pharma (United States)","ror":"https://ror.org/023annq56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112018"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Seehra","raw_affiliation_strings":["Acceleron Pharma, Cambridge, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acceleron Pharma, Cambridge, United States","institution_ids":["https://openalex.org/I4210112018"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5041514565"],"corresponding_institution_ids":["https://openalex.org/I4210112018"],"apc_list":{"value":3470,"currency":"USD","value_usd":3470},"apc_paid":null,"fwci":0.3954,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.58414123,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"17","issue":"9-10","first_page":"785","last_page":"785"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10441","display_name":"Muscle Physiology and Disorders","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10441","display_name":"Muscle Physiology and Disorders","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11501","display_name":"TGF-\u03b2 signaling in diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12400","display_name":"Neurogenetic and Muscular Disorders Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myostatin-inhibition","display_name":"myostatin inhibition","score":0.8610000014305115},{"id":"https://openalex.org/keywords/myostatin","display_name":"myostatin","score":0.8730000257492065},{"id":"https://openalex.org/keywords/activin-type-ii-receptor","display_name":"activin type II receptor","score":0.7210000157356262},{"id":"https://openalex.org/keywords/muscle-mass","display_name":"muscle mass","score":0.5720000267028809},{"id":"https://openalex.org/keywords/duchenne-muscular-dystrophy","display_name":"Duchenne muscular dystrophy","score":0.9409999847412109},{"id":"https://openalex.org/keywords/mdx-mice","display_name":"mdx mice","score":0.9950000047683716},{"id":"https://openalex.org/keywords/skeletal-muscle-growth","display_name":"skeletal muscle growth","score":0.6840000152587891},{"id":"https://openalex.org/keywords/fc-fusion-protein","display_name":"Fc fusion protein","score":0.46399998664855957}],"concepts":[{"id":"https://openalex.org/C2777488582","wikidata":"https://www.wikidata.org/wiki/Q29630","display_name":"Myostatin","level":3,"score":0.9764301776885986},{"id":"https://openalex.org/C2779959927","wikidata":"https://www.wikidata.org/wiki/Q1048687","display_name":"Skeletal muscle","level":2,"score":0.696101188659668},{"id":"https://openalex.org/C28406088","wikidata":"https://www.wikidata.org/wiki/Q5571762","display_name":"Extracellular","level":2,"score":0.5710304379463196},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5463784337043762},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5263611078262329},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5194551348686218},{"id":"https://openalex.org/C2775872116","wikidata":"https://www.wikidata.org/wiki/Q943203","display_name":"Gastrocnemius muscle","level":3,"score":0.4631136953830719},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4519217014312744},{"id":"https://openalex.org/C207583985","wikidata":"https://www.wikidata.org/wiki/Q128723","display_name":"Wild type","level":4,"score":0.44306686520576477},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.40848320722579956},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2920070290565491},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.2763631343841553},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.15664803981781006},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.051574885845184326}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.nmd.2007.06.086","doi":"https://doi.org/10.1016/j.nmd.2007.06.086","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.nmd.2007.06.086","pdf_url":null,"source":{"id":"https://openalex.org/S50004817","display_name":"Neuromuscular Disorders","issn_l":"0960-8966","issn":["0960-8966","1873-2364"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuromuscular Disorders","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8560000061988831}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2320217887","https://openalex.org/W2097680159","https://openalex.org/W2149993139","https://openalex.org/W2047284298","https://openalex.org/W2168426309","https://openalex.org/W2126809879","https://openalex.org/W7099197564","https://openalex.org/W2507377129","https://openalex.org/W2299658714","https://openalex.org/W2153537261"],"abstract_inverted_index":null,"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}